1796 – ADAMTS13 testing for the diagnosis of thrombotic thrombocytopenic purpura (TTP)

The Royal College of Pathologists of Australasia

New Medicare Benefits Schedule item.

Testing for ADAMTS13 enzyme activity and anti-ADAMTS13 antibody (ADAMTS13 autoantibody) testing for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Patients with reduced ADAMTS13 enzyme activity who do not have ADAMTS13 autoantibodies should undergo genetic testing for variants in the ADAMTS13 gene to identify potential cases of congenital TTP (cTTP).

Type: Investigative

Thrombotic thrombocytopenic purpura (TTP) is a rare condition where blood clots form in small blood vessels throughout the body. This causes low platelet and red blood cell counts in patients, which can lead to life threatening organ damage.

The most common form of TTP is immune-mediated or acquired (iTTP), presenting in adulthood due to the presence of acquired ADAMTS13 autoantibodies. TTP can also be hereditary or congenital (cTTP) in origin, often detected in childhood or during pregnancy as a result of variants in the ADAMTS13 gene.
 

Provide your input online

The following consultation deadlines apply:

• Pre-PASC consultation deadline: 14 March 2025
• Pre-MSAC consultation deadline: -

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 16 to 17 April 2025
• ESC meeting: -
• MSAC meeting: -

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.